Virtu Financial LLC Cidara Therapeutics, Inc. Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	BUY	$0.68 - $0.97 $51,942 - $74,094	76,386 Added 400.68%	95,450 $76,000
Q3 2023 Nov 14, 2023	BUY	$0.77 - $1.16 $14,679 - $22,114	19,064 New	19,064 $18,000
Q3 2022 Nov 07, 2022	SELL	$0.45 - $0.81 $2,248 - $4,047	-4,997 Reduced 19.3%	20,889 $13,000
Q2 2022 Aug 09, 2022	BUY	$0.43 - $0.91 $11,130 - $23,556	25,886 New	25,886 $13,000
Q1 2021 May 19, 2021	SELL	$2.06 - $3.01 $23,852 - $34,852	-11,579 Closed	0 $0

Q4 2020 Feb 24, 2021	BUY	$1.99 - $3.25 $23,042 - $37,631	11,579 New	11,579 $23,000
Q2 2020 Aug 07, 2020	SELL	$2.39 - $4.0 $56,081 - $93,860	-23,465 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$1.77 - $3.84 $41,533 - $90,105	23,465 New	23,465 $90,000
Q3 2019 Nov 20, 2019	SELL	$1.25 - $2.35 $45,857 - $86,212	-36,686 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$1.49 - $2.94 $33,009 - $65,132	22,154 Added 152.45%	36,686 $62,000
Q1 2018 May 14, 2018	BUY	$4.0 - $8.15 $58,128 - $118,435	14,532 New	14,532 $58,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $889M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.